Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company’s innovative nasal spray designed to block airborne allergens.
This approval from BRANY Institutional Review Board (granted June 18, 2026) is a key regulatory milestone for the Company. It confirms that the study protocol, patient consent forms, and trial materials have been reviewed and approved by the central IRB and satisfy applicable ethical and participant protection requirements.
The approved study, titled "Evaluation of the Efficacy, Safety, and Tolerability of NASARIXTM Allergy Blocker Compared to Saline Spray in Patients with Seasonal Allergic Rhinitis," is designed to assess the efficacy, safety, and tolerability of NASARIXTM in patients suffering from seasonal allergic rhinitis. The study will compare NASARIXTM against a saline spray control to evaluate symptom relief and overall patient outcomes.